ASX Announcements
ASX Announcements
2023
15 November 2023 – Results of Annual General Meeting
15 November 2023 – Annual General Meeting 2023 Presentation
31 October 2023 – Appendix 4C & Quarterly Report
17 October 2023 – Notice of Meeting, Proxy and Voting Guide
16 October 2023 – Antisense to Participate in upcoming Industry Conferences
9 October 2023 – Launch of Share Sale Facility for Unmarketable Parcels
28 September 2023 – New Data Published, and Patent Filed, for ATL1102 in ‘Long COVID’
26 September 2023 – New Preclinical Data for ATL1102 in Limb Girdle Muscular Dystrophy R2
28 August 2023 – Corporate Presentation_August 2023
25 August 2023 – Appendix 4E and Annual Report – 30 June 2023
21 August 2023 – Antisense Share Purchase Plan raises $3.26M
7 August 2023 – Commencement of Chief Executive Officer
26 July 2023 – Positive new DMD Combination Therapy Data in mdx mice
20 July 2023 – Intention to launch Share Purchase Plan
18 July 2023 – Institutional Placement and proposed Share Purchase Plan
27 June 2023 – MHRA Approval Received to Conduct Phase IIb Trial in the UK for ATL1102 in DMD
8 June 2023 – First Patient Dosed in AL1102 Phase IIb DMD Trial
6 June 2023 – Shareholder Newsletter
8 May 2023 – Chief Executive Officer and Managing Director Appointment
26 April 2023 – ATL1102 Phase IIb DMD trial – Bulgarian approval received with UK and Australian approval process advancing
17 April 2023 – Quarterly Activities Report & Appendix 4C
14 March 2023 – Dosing Commenced in the ATL1102 toxicology study
14 February 2023 – First approval received for ATL1102 Phase IIb DMD clinical trial
13 February 2023 – Dosing commenced in Limb Girdle Muscular Dystrophy R2 animal study
1 February 2023 – Positive outcomes in DMD combination therapy animal study
25 January 2023 – Quarterly Activities Report & Appendix 4C
2022
19 December 2022 – Clinical Trial Application submitted for ATL1102 Phase IIb DMD trial conduct in Europe
17th November 2022 – Annual General Meeting 2022 Presentation
Annual General Meeting results
16th November 2022 – Antisense Therapeutics CEO announces retirement
14th November 2022 – ATL1102 toxicology study to support clinical program in the US
19th October 2022 – Notice of Annual General Meeting & Proxy Form
14 October 2022 – Receipt of further R&D Tax Incentive Payment
Non-Executive Director retirement
5 October 2022 – Company Appointment – Chief Commercial Officer
12 September 2022 – Dosing commenced in DMD combination therapy study
7 September 2022 – ATL1102 for DMD: Revised Clinical Development Plans
31 August 2022 – Appendix 4E & Full Statutory Accounts
19 August 2022 – Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
28 July 2022 – Investor Presentation
27 July 2022 – Quarterly Activities/Appendix 4C
13 July 2022 – ATL1102 for DMD Clinical Trial Application Submitted in Europe
28 June 2022 – Proteomics and disease marker identification in DMD Webinar
24 June 2022 – ANP Presentation – PPMD 2022 Annual Conference
20 June 2022 – New Indication for ATL1102 for Limb Girdle Muscular Dystrophy R2
15 June 2022 – Presentation at CNS Summit
27 May 2022 – Investor Presentation
29 April 2022 – Bonus Option Issue Letter to Shareholders
28 April 2022 – Quarterly Update & Appendix 4C_31 Mar 22
14 April 2022 – Receipt of RD Tax Incentive payment
12 April 2022 – Bonus Option Offer
14 March 2022 – Significant modulation of two bone morphogenetic proteins supports potential of ATL1102 for improving bone density in DMD
1 March 2022 – Poster Presentation at 2022 MDA Clinical & Scientific Conference
24 February 2022 – Long COVID-19 strategic collaboration with US Experts
23 February 2022 – Half Yearly Report and Accounts
8 February 2022 – ATL1102 MCRI Collaboration Dosing Commenced
27 January 2022 – Quarterly Update and Apendix 4C